A big hurdle in small molecule drug discovery screening is confidently identifying positive hits in a timely manner. Screening fragment libraries is challenging with current methodologies that are either time-consuming or lack detection sensitivity. Dianthus NT.23PicoDuo utilizes a biophysical detection method for fast, precise and confident hit identification, target validation and lead optimization. An example of single-dose and affinity screening against histone methylase G9a, known to be associated with cancer onset, will be discussed.
Most recent content
25:16Dynamic Light Scattering (DLS) is a technique that allows researchers to accurately size their biologic molecules and determine the distribution of particle sizes in a solution. In order to turn scatt
25:01Watch this webinar if you’re working in the field of small molecule drug discovery and want to learn how scientists in this field use biophysical tools to search for the most promising lead compounds.
28:21AbbVie preformulation is an early discovery biologics group working to optimise antibodies prior to downstream assays and clinical delivery. Join Brittney Mills, PhD, as she explains how AbbVie uses
14:01The desire to use technology that allows you to study membrane proteins in close-to-native conditions is specifically important when it comes to interaction measurements. It’s always a question how mu
12:06What you’ll learn It’s very common to experience low expression levels when producing membrane proteins — plus they’re finicky and unstable when they're outside of their native environment. Just know
56:52Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com
35:47Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
35:24Effect of different SARS-CoV-2 variants on COVID 19 assays and vaccines
SARS-CoV-2, the causative agent of COVID-19, has an ssRNA genome of almost 30kb that encodes for a total of 26 proteins. Among the four structural viral protein, in particular the S protein stands out
33:11Dr. Leah Pandiscia and Dr. Daniel Turman review how to integrate the Prometheus Panta and Monolith instruments in a characterization workflow demonstration, showing how to maximize stability and funct
22:36Hear how Dr. Sathya Venkataramani from Janssen Biotherapeutics maximized protein stability using the Prometheus in a real life case study about the design and characterization of antibody-based drugs.
29:22Learn about the causes of protein aggregation and how to implement the best solutions to enhance protein stability with Dr. John Carpenter from the University of Colorado. He presented as one of three
27:20Explore the complexities and drivers of molecular interactions with Dr. Tom Laue from the University of New Hampshire. He presented as a keynote speaker in the Protein Stability & Function: Can't have
1:32:25Let's catalyze - biophysical insights into enzymes
Enzymes are nature's engine for many processes. Diving into the stability and function of enzymes will give us a better understanding of these processes. In this webinar, you will learn: -what biophy
42:46Join this case study and walk through of Prometheus Panta. Make your formulation workflow more efficient and effective with simultaneous, multi-parameter stability characterization. What you’ll lear
1:06:54Join this e-demo on the Prometheus Panta. Learn how to collect thermal unfolding, particle sizing, and aggregation data on a single platform using the NIST mAb. The growing complexity of therapeutic
34:16Join this webinar to learn about the physical phenomenon that drives Dynamic Light Scattering (DLS), and see a few examples of how DLS gives you deeper insights.
38:40Gene therapy promises to treat and potentially cure a disease by correcting its underlying genetic cause. While gene therapies that utilize AAV vectors have shown encouraging results —including a few
18:48Join Thomas Schubert, CEO of 2bind, as he walks through experiments done on the Prometheus Panta to determine the optimal buffer for a vaccine candidate.
25:40Are you struggling to tame your mischievous membrane proteins? Find out how NanoTemper can help you to characterize even the most challenging membrane protein samples. You will learn how Prometheus ca
12:14Monoclonal antibodies and therapeutic proteins for vaccines require extensive stability characterization during their development phase to improve their probability of successful treatment. We will di